Paris

• ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting
  2025-521710-25-00 4 2025-12-04 Lewy Body Dementia Psychosis (LBDP)
• RHIBOT II - Medium- and long-term efficacy of two ultrasound-guided intra-articular injections of onabotulinumtoxinA (Botox®) combined with … Recruiting
  2024-515028-35-00 5 2025-12-03 Adults aged at least 18 years with painful base-of-thumb osteoarthriti
• Trial of Tepotinib compared to Standard Treatment in Patients with Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer Recruiting
  2024-519971-25-00 5 2025-12-03 Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer
• Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting
  2025-521381-10-00 5 2025-12-03 Moderately to Severely Active Ulcerative Colitis
• Dapagliflozine for cardio-renal protection at ICU discharge Recruiting
  2024-510941-32-00 5 2025-12-02 Adult patients discharged alive from ICU with a decreased eGFR, and/or
• A study to find out how EMPAgliflozin is tolerated and if it helps children and adolescents with chronic KIDNEY disease (EMPA-KIDNEY Kids) Recruiting
  2024-512577-27-00 5 2025-12-02 Chronic kidney disease in paediatric patients
• A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program … Recruiting
  2025-521281-97-00 5 2025-12-02 Non-Small Cell Lung Cancer (NSCLC)
• A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-thr … Recruiting
  2025-521697-34-00 5 2025-12-01 Peanut allergy
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting
  2025-520612-34-00 5 2025-11-28 Agitation Associated with Alzheimer’s Disease
• A Study of the Long-Term Safety and Efficacy of VX-670 in Patients With Myotonic Dystrophy Type I Recruiting
  2024-517983-47-00 9 2025-11-25 Myotonic Dystrophy
• Risk-adapted adjuvant chemotherapy guided by the tumour stage for operated pancreatic adenocarcinoma following neoadjuvant chemotherapy with … Recruiting
  2024-519048-33-00 10 2025-11-25 resected pancreatic adenocarcinoma
• A study to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo®, in combination with mFOLFOX6 and bevacizumab versus … Recruiting
  2024-519590-19-00 4 2025-11-25 PD-L1 positive advanced colorectal cancer
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Recruiting
  2024-519727-18-00 1 2025-11-25 Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer
• Momelotinib in VEXAS syndrome Recruiting
  2024-519779-24-00 4 2025-11-25 VEXAS (VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC) syndr
• Safety and Efficacy of Tarperprumig in Adult Participants with ANCA-Associated Vasculitis Recruiting
  2025-521706-17-00 4 2025-11-25 Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
• A clinical study of MK-1084 in people with advanced solid tumors (MK 1084-014) Recruiting
  2025-521737-91-00 4 2025-11-25 Neoplasm malignant with KRAS G12C mutation
• Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting
  2025-520927-26-00 5 2025-11-24 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• RLY-2608-201-Ph2 Study of RLY-2608 in PROS and PIK3CA Driven Malformations Recruiting
  2024-518895-30-00 4 2025-11-21 PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA
• A Follow-Up Shiftability Study of Arbaclofen with an Open-Label Extension for the study of Biomarkers for Treatment for Social Function in C … Recruiting
  2023-508407-20-00 5 2025-11-20 autism spectrum disorder
• A Phase Ib/II first-in-human, multicentre, open-label, multiple ascending dose study of S230815 in paediatric participants with KCNT1-relate … Recruiting
  2024-513332-17-00 7 2025-11-19 KCNT1-related Developmental and Epileptic Encephalopathy
• TARLATEM : Combination of TARLAtamab and TEMozolomide in patients with central nervous system tumors. A multicenter, open-label Phase I/II t … Recruiting
  2023-510568-11-00 9 2025-11-18 High grade brain tumors
• A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M … Recruiting
  2025-521511-40-00 10 2025-11-18 metastatic non-small cell lung cancer
• A randomized multicenter Phase II trial evaluating oral pooled fecal microbiotherapy (MaaT033) concomitant to Cemiplimab (CB) versus best in … Recruiting
  2024-517018-14-00 4 2025-11-17 Advanced non-small cell lung cancer
• TACTIC : MP0317, A TUMOR TARGETING FAP DEPENDENT CD40 AGONIST DARPIN, IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN FIRST LINE TREATMENT FOR PAT … Recruiting
  2024-520029-35-01 4 2025-11-17 ADVANCED BILIARY TRACT CARCINOMA

Showing 577–600 of 2,286 trials